← Evidence map

ArticleJournal of thoracic disease2026

Refining first-line therapy in ALK-positive non-small cell lung cancer: final overall survival from the ALEX trial and an evolving treatment landscape.

Mitchell Boshkos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Refining first-line therapy in ALK-positive non-small cell lung cancer: final overall survival from the ALEX trial and an evolving treatment landscape. | OpenQuestion